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The DHFR mediated gene amplification employed for selection of recombinant 
Chinese hamster ovary (rCHO) clones was evaluated by single and multiple step selection of 
methotrexate (MTX). Multiple step selection of MTX resulted in cells with high amplified 
copies of erythropoietin (EPO) gene. Expression of EPO rapidly increased with increasing 
MTX concentration up to 1000 nM, further increased to 2000 nM does not affect the 
expression. After the MTX selection, cells grown in the presence of MTX were more stable 
and retained similar amounts of EPO expression & gene copies until 50 doublings. Whereas, 
cells grown in the absence of MTX were unstable and retained only 50% of initial EPO 
expression & gene copies at the 50th doubling. Scale-up from culture flask to wave bioreactor 
increases EPO yield, the novel wave bioreactor with a working volume of 1 liter could 
produce more than 0.56 g of EPO in 3 weeks, with a volumetric productivity of 24 mg/l/day 
and specific productivity of 5.93 µg/106cells/day. Simple two step chromatographic 
purification process was developed with relatively high yield and purity of EPO using blue 
sepharose affinity chromatography combined with Q-sepharose ion exchange 
chromatography.  A single protein zone with molecular mass of 32-38kDa was appeared in 
SDS-PAGE analysis of the purified rHuEPO. Densitometric scanning of gels demonstrated, 
>90% purity of final EPO, giving a 42% recovery.  
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The most widely used mammalian 
expression system is the gene amplification 
procedure offered by the use of dihydrofolate 
reductase-deficient (DHFR-) CHO cells with 
DHFR-mediated gene amplification (Chung 
et al., 2003). Methotrexate binds and inhibits 
the DHFR enzyme, leading to cell death 
through the depletion of reduced folates 
(Hsieh et al., 2009). However, DHFR- CHO 
cells, which have taken up an expression 
vector containing the DHFR gene, can 
develop resistance to it by amplifying the 
DHFR gene. Since the gene of interest is 
integrated into same genetic locus as DHFR, 
the gene of interest is amplified as well, 
leading to increased production of the 
recombinant protein (Jun et al., 2005).  
 
Gu et al. (1996) showed that increasing 
the foreign gene copy number using the 
DHFR gene amplification system results in 
severe growth rate reduction. Until now, the 
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major factor causing metabolic burden in 
DHFR gene amplification system has not 
been identified. For the production of 
recombinant proteins, not only the expression 
level but also the stability of amplified genes 
is critical. Instability of the amplified genes in 
the absence of selective pressure has been 
reported (Sinacore et al., 1995). Therefore, 
understanding the effect of MTX 
concentration on the cell growth and protein 
expression is important. It’s also essential to 
investigate whether the rCHO cells 
expressing human EPO gene are stable or not.  
 
Bioreactors are complex and 
expensive devices, yet they do not provide an 
ideal environment for mammalian cell 
growth due to high local fluid shear and 
bubble aeration. To avo1id problems 
associated with cell culture vessels, a new 
wave bioreactor was designed by Singh 
(1999). Wave bioreactors are an excellent 
choice for the elimination of need of cleaning, 
sterilization and associated validation 
requirements (Liangzhi et al., 2003). Batch 
(Yoon et al., 2004), fed batch (Bibila and 
Robinson, 1995), repeated batch (Takagi et al., 
2001), continuous (Europa et al., 2000) and 
perfusion (Ryll et al., 2000) mammalian cell 
cultures are main modes of the industrial 
operation for large scale production of 
recombinant proteins for human therapy (Hu 
and Aunins, 1997; Kretzmer, 2002). Repeated 
batch culture is easy to operate and low risk 
of contamination (Yamamoto et al., 2000). 
However, there is no universal approach to 
optimize conditions for all animal cell culture 
systems. Each bioprocess must be optimized 
with respect to a specific set of parameters. 
These include cell growth, cell yield and 
specific productivity.  
 
Methods of EPO purification have 
subsequently been developed (Broudy et al., 
1988; Inoue et al., 1994; Ben-Ghanem et al., 
1994), more efficient in terms of yield and 
specific activity, but still conceived for lab-
scale preparations. Zanette et al. (2003) and 
Hu et al. (2004) described an improved, 
inexpensive industrial scale purification of 
EPO from mammalian cell cultures. Although 
resulting in good specific activity and yields, 
they cannot be easily modified to suit 
biopharmaceutical industry level purification 
for a number of reasons. The present study 
focuses on the aspects of MTX selection 
procedure, optimal MTX concentration, and 
stability of the amplified genes in presence 
and absence of MTX for the rCHO cells, 
followed by scale-up and down stream 
processing of the EPO. 
 
Materials and methods 
 
Cell culture: A cloned rCHO cell line (CHO-
EPO) manipulated to secrete recombinant 
human erythropoietin was used in this work. 
These cells were kindly provided by Genomix 
Biotech Inc. (Atlanta, USA). Briefly, they were 
established by transfection of a vector 
containing DHFR and human EPO genes into 
DHFR deficient CHO cells. Excell 325 serum 
free medium (SAFC Biosciences, Kansas, 
USA) was used in this study, medium is 
supplemented with 4 mM glutamax (Gibco-
Invitrogen) & 10µg/ml bovine insulin 
(Sigma).  
 
In the multistep selection of MTX, selections 
were made sequentially in medium 
containing 50, 200, 500, 1000 and 2000 nM 
MTX. Exponentially growing cells (4×105 
cells/ml) were cultured in 75 cm2 flask 
containing 15 ml of Excel 325 medium. 
Medium was changed every 2-3 days for a 
period of 10 days, populations that reached 
normal growth at the chosen level of drug 
were used for the next round of selection, 
whereas in single step selection, cells were 
grown at a time in all the concentrations of 
MTX. Clones isolated at 500 nM MTX were 
grown in the absence and presence of MTX 
for the determination of amplified gene 
stability. Cells were always passaged upon 
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reaching 106 cells/ml by centrifugation and 
fed with fresh medium. Cell growth and 
protein production characteristics were 
monitored over a period of 50 doublings. 
 
Scale-up in wave bioreactor: Cultures were 
carried out in wave 2-L perfusion cell bag (GE 
Health Care, USA) using the Amicon cell 
culture system (Amicon, MA, USA). 
Exponentially growing cells (2×105 cells /ml) 
in the T-flask were transferred directly in to 
2-L cell bag with 200 ml of medium 
containing 500 nM MTX. Aeration (mixture of 
air & 5% CO2) and agitations were 
maintained initially at 0.1 lpm (litre per 
minute) and 20 rpm (rocks per minute), 
further increased to 0.2 lpm and 30 rpm, 
depending on the glucose consumption and 
cell growth, fresh medium was added.  
 
Purification 
 
Clarification and diafiltration: Serum-free 
harvest collected from the wave bioreactor 
over a period of 10 harvests was centrifuged 
at 3000 rpm for 10 minutes, supernatant was 
filtered through 0.45 µm membrane using a 
Pellicon system (Millipore) to remove the 
remaining cells and debris. After the 
clarification, filtrate was concentrated by TFF 
(tangential flow filtration) system using a 10 
kDa cut-off membrane (Millipore) to about 2 
fold volume reductions. Conductivity was 
adjusted to 10-15 mS/cm with phosphate 
buffer.  
 
Affinity chromatography and buffer 
exchange: A XK26 glass column (Pharmacia, 
30mm internal diameter and 80mm length) 
was packed with 50 ml of Blue sepharose 6 
fast flow matrix (Amersham). The column 
temperature and flow rate were maintained 
at 20ºC and 10 ml/min respectively 
throughout the process. Column was 
equilibrated with 4 column volumes of PBS 
and regenerated with PBS containing 1.4 M 
NaCl and 8 M urea. Column was washed 
with PBS before loading with concentrated 
supernatant, again washed with 3 column 
volumes of PBS until absorbance at 280 nm of 
the eluate was nearly zero. EPO protein was 
eluted with 1.5 M NaCl, peak containing the 
active fractions was pooled and buffer 
exchanged against 20mM Tris (pH - 8.0) by 
TFF using 10 kDa cut off membrane 
(Millipore). 
 
Ion-exchange chromatography: C26/40 
Pharmacia column (30 mm diameter and 90 
mm length) was packed with 65 ml of Q-
sepharose matrix (Amersham), column 
temperature was approximately 20ºC and 
flow rate was maintained at 10ml/min. 
Column was equilibrated with water and 
charged with 20mM Tris containing 1.4M 
NaCl. After re-equilibrated with 20mM Tris 
(pH-8.0), desalted blue sepharose elute was 
loaded on to the column. Column was 
washed with acid buffer (6M urea, 1mM 
glycine, 20µM CuSO4, pH-4.7) followed by 
second wash with 20 mM Tris. EPO protein 
was then eluted with 20 mM Tris, 140 mM 
NaCl (pH-8.0). Fraction containing EPO was 
sterilized by passing through a 0.22 µm pore 
size filter. 
 
Analytical Methods:  
Viable and total cell concentrations were 
determined by the trypan blue exclusion 
method using a haemocytometer (Patterson, 
1979). Secreted EPO concentrations were 
quantified by ELISA (EPO.96, MD Bioscience, 
USA), as for manufacturer’s instructions. 
Glucose concentration was determined by 
enzymatic method (GOP/POD method, Excel 
diagnostics, India). Doubling time (Td) was 
calculated by the following formula, Td= (t2-
t1) × log (2)/log (q2/q1), [q1 - growth quantity 
at t1 (time 1) and q2 - growth quantity at t2 
(time 2)]. 
 
SDS-PAGE analysis: A discontinuous SDS-
PAGE performed according to Laemmli 
(Laemmli, 1970) using the Bio-Rad X cell sure 
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lock vertical slab gel unit and gel 
documentation systems. Electrophoresis was 
carried out in 4-20% precast gels (Invitrogen, 
USA) and gels were silver stained (Blum et al., 
1987).  
Purified EPO samples, subjected to SDS-
PAGE, transferred to nitrocellulose 
membrane and stained with anti-EPO 
primary antibodies (1:1000 dilution, Santa 
Cruz Biotechnology, USA) for 2 hrs at 4ºC, 
after washing with PBS containing Tween 20 
(0.05%), blots were probed with 1:2000 
dilution of goat anti-rabbit horseradish 
peroxidase conjugated second antibodies 
(Santa Cruz Biotechnology, USA) for 1 hr at 
RT. The enhanced chemiluminescent 
detection (Roche) was used to develop blot 
and fluorescence was detected by using 
Vilbert chemicapt. 
 
IEF analysis of EPO: Isoelectric focusing was 
performed on a readymade immobilized pH 
gradient strips (IPG pH 3-10, Bio-Rad) using 
Bio-Rad PROTEIN IEF cell. IPG strips were 
rehydrated in the presence of urea using 
Resolyte (Merck ltd.). Samples containing 
purified EPO was applied to the strip and 
then subjected to gradient voltage (250 – 
3500V) for 3 h at 20°C. After IEF, the strip was 
then subjected to SDS-PAGE and western 
blotting.  
 
Statistical Analysis: The experiments were 
carried out in triplicate and results are 
expressed as mean±SD. Significant 
differences (P<0.05) were determined by the 
Student t test.  
 
DNA extraction and PCR 
For the determination of amplified gene 
copies, genomic DNA was isolated from cells 
using the method described by Sharma et al. 
(1993). DNA was quantitated spectro-
photometrically (Nanodrop, DuPont, USA) 
and equal amounts of templates were 
amplified using EPO gene specific primers 
(Forward-5' TCA CTG TCC CAG ACA CCA 
AA 3' and Reverse-5' CAC TGA CGG CTT 
TAT CCA CA 3') and GAPDH primers 
(Forward-5'TGG CAA AGT GGA AGT TGT 
TG 3' and Reverse- 5' GAT CTC GCT CCT 
GGA AGA TG 3'). Equal volume of PCR 
products were analysed by agarose gel (0.8%) 
electrophoresis using Bio-Rad gel 
documentation system. 
 
Results and discussion 
 
Effect of MTX on CHO cell growth  
To isolate higher resistant clones, we first 
performed multistep selection of MTX. As 
shown in figure 1(A), total viable cells in the 
control flask at the end of cultivation was 
98.2±1.9×106, whereas 66.3±2.9×106 (50nM), 
61.9±3.3×106 (200nM), 54.7±2.3×106 (500nM), 
25.2±2.6×106 (1000nM) and 8.7±0.25×106 
(2000nM) at various levels of MTX, 
respectively. The first step in this selection 
(50nM) appears to be 32.5% of growth 
inhibition than the control population. Cells 
treated between 50 to 500 nM drug 
concentrations had negligible growth 
inhibition. Whereas, more than 50% growth 
inhibition was observed by 1000 nM MTX 
compared to 500 nM. Cell concentration was 
rapidly decreased at highest drug 
concentration (2000nM), this may be due to 
the greater increase in cytotoxicity. Viability 
is very similar in  50 nM, 200 nM & 500 nM 
cultures, although at the end, viability 
reached almost to that of control, a significant 
difference is noticed in first two days. Rapid 
drop in viability was seen by both 1000nM & 
2000nM MTX [Fig: 1(B)].  
 
Figure 1(D) &(E) shows typical CHO cell 
growth during the single step selection. There 
is a rapid suppression of cell growth was 
observed at 200 nM (37.8%, Student’s t-test 
p<0.0002) and 500 nM (56.7%, Student’s t-test 
p<0.0012) than at 50 nM drug concentration. 
The viability count decreased drastically at 
concentrations of 200 nM and 500 nM of the 
drug. No significant cell concentration and 
 
Rambabu Surabattula et al. / Research in Biotechnology, 2(3): 58-74, 2011 
62 
 
viability was observed at higher MTX 
concentrations (1000 &2000nM). It has been 
well documented that selective gene 
amplification is one mechanism by which 
cultured mammalian cells become resistant to 
cytotoxic drugs (Brown et al., 1983). As a first 
step to develop the effective selection 
strategy, two selection processes were 
compared. There are, to date, no 
experimental data is available to directly 
compare them for CHO cells. In the selection 
based on gradual MTX increments, it took 
more than 40 days to obtain clones with high 
resistant. Cells were sensitive to MTX initially 
during the every increment in MTX 
concentration up to 1000 nM. Decrease in cell 
concentration and viability (52%) was 
observed at a concentration of 2000 nM of 
MTX, hence this concentration was avoided 
for the further analysis. Culturing cells at 
very high MTX concentration, will effect the 
cell growth, secretion efficiency, and 
intracellular degradation may outweigh the 
beneficial effect of enhanced protein 
productivity (Kim et al., 1998). 
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Figure 1. CHO cell concentration, viability and EPO expression at various levels of MTX 
concentration.  (A) cell concentration, (B) viability, (C) EPO yields at gradual increase in MTX 
concentration. (D) cell concentration, (E) viability, (F) EPO yields at direct increase in MTX 
concentration. Bars indicate standard deviation. 
 
Since, the gradual selection procedure is time 
taking, we have used the direct selection 
procedure to select the cells against MTX. The 
cell concentration was rapidly decreased with 
increased amounts of MTX by this process 
and the cell viability was started decreasing 
even at 200 nM MTX. Cells were not even 
grown at the higher levels of MTX (1000 & 
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2000nM). The present study suggests multi 
step selection of MTX for recombinant CHO 
cells, in order to achieve high EPO gene 
copies and optimal production of the protein.  
 
Gene amplification and Protein expression 
EPO gene amplification and increased protein 
expressions were determined during the both 
selections, MTX selected cells were cultured 
in T-flasks containing the corresponding level 
of MTX. Supernatants were analyzed for 
protein expression by ELISA, it was observed 
that the EPO expression was rapidly 
increased with increasing levels of MTX up to 
1000 nM by the gradual selection [Fig: 1(C)]. 
However, further increase of MTX level up to 
2000 nM did not increase EPO expression 
(data not shown), this may be due to poor cell 
growth and viability. EPO expression was not 
significantly increased with increasing level 
of MTX by direct selection [Fig: 1(F)]. Higher 
level of MTX concentrations (1000 & 2000nM) 
were eliminated from this analysis due to 
poor cell growth.  
 
To investigate whether the increased EPO 
expression was related to changes in the EPO 
gene copy numbers, genomic DNA isolated 
from CHO cells at each MTX level was 
characterized by PCR. Increasing intensity of 
EPO gene bands were clearly observed by 
gradual selection of MTX [Fig: 2(A)], this 
indicates EPO gene amplification following 
MTX treatment (Pendse et al., 1992). 
Densitometric tracing of the bands indicated 
no significant increase in intensities was 
observed by direct MTX selection [Fig: 2(C)]. 
Very similar band intensities were observed 
for GAPDH gene (control) in all samples of 
gradual and direct selections [Fig: 2(B) & 
2(D)]. 
 
PCR analysis revealed that the enhancement 
of EPO protein was related to the extent of 
EPO gene amplification. Finally, the EPO 
expression was increased 6 folds (at 1000nM) 
higher than the control cultures by the 
gradual increase in MTX levels. Eventhough 
EPO production was increased significantly 
at 1000 nM MTX, but the cell viability was not 
reached more than 72%, this indicates, cells 
did not get fully resistance at this 
concentration of MTX. Sialic acid content is 
essential for the glycoproteins to maintain 
circulatory lifetime, desialylation of 
glycoproteins is caused by sialidases released 
from dead cells, especially during the later 
phase of cell culture (Ferrari et al., 1998). So it 
is essential to maintain the high viability 
during the production of glycoproteins. 
Hence, it is suggested that 500 nM MTX 
concentrations is optimal for the production 
of recombinant EPO by CHO cells. 
 
Amplified gene stability in the absence of 
MTX 
MTX selected (500nM) cells were cultivated 
in the absence as well as in the presence of 
corresponding level of MTX. Cell growth rate 
without MTX was higher for most part than 
with MTX [Fig: 3(A)], this improvement was 
probably as a result of no cytotoxicity and 
gene loss (Kim et al., 1998). This could be 
possible because high producing clones are 
more susceptible to environmental changes 
and display lower cell growth rate than low 
or nonproducing clones due to the effect of 
DHFR and foreign gene amplification (Gu et 
al., 1994). In the absence of MTX, significant 
decrease in EPO production was seen [Fig: 
3(B)]. In the initial doublings (up to 5th), very 
similar expression levels were obtained in 
both cases, furthermore, it was decreased 
(15th doublings onwards) in the absence of 
MTX. Cells grown in the presence of MTX 
were more stable and retained the similar 
amounts of EPO production in the entire 
cultivation.  
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Figure 2. PCR analyses of EPO and GAPDH genes. (A) EPO, (B) GAPDH during the gradual selection 
(Lane 1: 100bp marker, Lane 2: Control, Lane 3: 50nM, Lane 4: 200nM, Lane 5: 500nM & Lane 6: 1000nM 
MTX conc.). (C) EPO, (D) GAPDH during the direct selection (Lane 1: 100bp marker, Lane 2: Control, 
Lane 3: 50nM, Lane 4: 200nM, Lane 5: 500nM MTX conc.). 
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Figure 3. (A) Growth and (B) EPO production characteristics of CHO cells during the culture in the 
presence and absence of MTX (500nM). PCR analysis of EPO gene during the long term cultivation of 
CHO cells in the absence (C) and presence of MTX (D). Lane 1: 100bp marker, Lane 2: at 5th doubling, 
Lane 3: at 20th doubling, Lane 4: at 35th doubling and Lane 5: at 50th doubling. Cell growth was expressed 
as population doublings per day. 
 
 
 
Figure 4. Growth of rCHO cells during the repeated batch cultivation in 2-L wave bioreactor. (A) day 2, 
(B) day 8, (C) day 13 and (D) day 23. 
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Changes in gene copy number were 
examined by comparison of PCR products on 
agarose gels. Cells retained most gene copies 
in the presence of MTX during the entire 
cultivation [Fig: 3(D)], whereas, only 50% of 
initial gene copies were retained by the cells 
in the absence of MTX [Fig: 3(C)]. When the 
genes are unstable, they reside on extra 
chromosomal elements, such elements 
replicate in the cell cycle and unequally 
distribute in to daughter cells, resulting in 
their instability (Schimke, 1984). As observed, 
decreased EPO production in the absence of 
MTX displayed the most significant loss of 
gene copies. It was clearly observed that the 
decreased level of protein expression was 
almost 50% lower in the absence of MTX than 
in presence. Similar to the protein expression, 
only 50% of initial EPO gene copies were 
retained by the cells in the absence of MTX. 
This is in correlation with the elevated DHFR 
levels that are characteristically unstable, 
when cells are grown under the absence of 
MTX for short time periods (up to 50 
doublings) (Kaufman and Schimke, 1981; 
Weidle et al., 1988). 
 
Table 1. Repeated batch process in wave bioreactor (harvest details) 
 
Harvest 
No 
Harvest 
Day 
Cell viability 
(%) 
Viable cells 
(per ml) 
Glucose 
content (mg/l) 
EPO       
(mg/l) 
1 5 96.1±0.60 1.01±0.09×106 1.69±0.09 29.90±0.46 
2 7 96.4±0.52 2.10±0.10×106 1.60±0.10 21.20±1.20 
3 9 96.6±0.12 3.18±0.14×106 1.30±0.04 35.36±0.80 
4 11 96.0±0.62 4.19±0.13×106 1.25±0.03 49.20±0.87 
5 13 95.7±0.90 5.12±0.12×106 1.19±0.02 65.10±1.10 
6 15 * * 1.11±0.09 75.00±1.20 
7 17 * * 1.22±0.09 77.27±0.50 
8 19 * * 1.33±0.05 75.10±0.90 
9 21 * * 1.42±0.03 69.10±0.96 
10 23 * * 1.64±0.05 63.20±0.50 
Same volume of fresh medium was added after every harvest.  
* indicates the ‘no cell count and viability’ was measured due to cell aggregates 
 
Scale-up of EPO expression in wave 
bioreactor 
The repeated-batch parameters were 
optimized for the scale-up of EPO production 
in 2-L wave bioreactor. Initially cells were 
grown up to approximately 1.0×106 cells per 
ml and the culture was diluted with fresh 
medium to get a density of 5×105 cells/ml. 
When the maximum working volume 
(1000ml) reached in wave cell bag, 95% of the 
culture supernatant was drawn through 
perfusion filter and replaced the drawn 
culture volume with fresh medium to initiate 
subsequent production cycles. Depending on 
the glucose consumption and medium colour 
changes (red to light yellowish), medium was 
replaced (harvested) with fresh medium as 
required. Initial glucose concentration was 
maintained at 3.2 g/l up to first 4 harvests 
and further it was increased to 4.2 g/l to 
compensate the glucose depletion at higher 
cell density. Batch was stopped after the 23rd 
day of cultivation (10th harvest), where the 
cell viability, glucose consumption and EPO 
production were started decrease 
significantly.  
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Figure 5. SDS-PAGE of fractions from blue sepharose (Lane 2,3,4) & Q-sepharose chromatography (Lane 
7,8,9,10). EPO eluted with various concentrations of NaCl was analyzed by 4-20% SDS-PAGE. Lane 1: 
protein marker (Cat no: 10747-012, Invitrogen, Carlsbad, CA), lane 2: eluate at 1M NaCl, lane 3: eluate at 
1.5 M NaCl, lane 4: eluate at 2 M NaCl, lane 5: concentrated cell culture supernatant, Lane 6: blue 
sepharose eluate (before loading to Q-sepharose), lane 7: eluate at 140 mM NaCl, lane 8: eluate at 250 mM 
NaCl, lane 9: eluate at 500 mM NaCl and lane 10: eluate at 1.4 M NaCl. 
 
Cell concentration was gradually increased to 
5.1±0.11×106cells/ml and viability was 
maintained above 95% up to 13th day of 
culture (Table: 1). Aggregates (≈25 
cells/aggregate) were observed at this high 
cell density and cell counts were not taken 
properly due to cell aggregations (Fig: 4). 
Large aggregates (≈70-100 cells/aggregate) 
were seen at the end of cultivation, this may 
be due to the high cell density (Yamamoto et 
al., 2000). Small aggregates (≈5-
6cells/aggregate) were disintegrated using 
sterile pipette and cells were counted at initial 
days of cultivation, but large aggregates were 
not disintegrated by the pipette and gave 
false results on cell number and viability. 
Glucose consumption was increased 
gradually up to the 15th day and slightly 
decreased from 17th to 23rd day (Table: 1), 
decrease in glucose consumption (17th to 23rd) 
could be due to decrease in cell growth and 
increased aggregates (Han et al., 2006). EPO 
yields were increased gradually up to 17th 
day (Table: 1) and slightly decreased from the 
19th day, this correlates well with the glucose 
consumption, where it was started decrease 
at 17th day. The novel wave bioreactor with a 
working volume of 1 litre could produce 
more than 0.56 g of EPO in 3 weeks, with a 
volumetric productivity of 24 mg/l/day, the 
volumetric productivity was calculated by 
dividing the total product concentration by 
the culture time. Specific productivity of 5.93 
µg/106cells/day was obtained between 5th to 
13th days of culture. The overall specific 
production rate of EPO was determined from 
the gradient of the plot of the accumulated 
EPO production against the integral from 
time zero of cell number-time (Renard et al., 
1988). Increasing protein yields and thereby 
reducing production costs is a major 
biotechnology target (Simone et al., 2003). 
EPO 
50 kDa 
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However, major accumulation of product 
requires a high cell density, high cell density 
can be carried out by repeated batch 
cultivation (Takagi et al., 2001) and batch-
refeed process can be the most efficient route 
to a highly productive process (Hammill et 
al., 2000). In the present study, highest cell 
density was obtained on 13th day of repeated 
batch cultivation, due to the large aggregate 
formation, cell counts were not taken during 
further cultivation. When cell density reached 
more than one million cells per ml, CHO cells 
tend to form aggregates during the repeated 
batch cultivation (Yamamoto et al., 2000). 
Similarly high viability was seen up to the 
day 13. Glucose consumption and EPO 
productions were increased gradually up to 
17th day and slightly decreased from the 19th 
day to end of the cultivation. The decreased 
glucose consumption rate indicates the 
decrease in cell growth (Bibila et al., 1994). 
 
To maintain the protein quality, it was 
decided to stop the repeated batch at 23rd day, 
even though rapid decrease in glucose 
consumption and EPO yields were not seen. 
Proteases (Gramer and Goochee, 1993) and 
sialidases (Elliott et al., 2003) released into 
culture medium from the dead cells during 
the cultivation of CHO cells, the general 
concern of these proteins activity may affect 
the quality of the recombinant product. 
Harvesting the product before extensive cell 
lysis occurs can readily reduce the extent of 
extracellular desialylation (Ferrari et al., 1998). 
The total volumetric productivity of EPO by 
the repeated batch using wave bioreactor 
could increase to gram quantity by scaling-up 
in large wave bioreactors. 
 
                        
Figure 6. Analysis of purified EPO, (A) 2µg of both purified and commercial standard EPO was analyzed 
by 12% SDS-PAGE and detected by silver stain, lane 1: EPO standard (EPREX-4000, Johnson & Johnson, 
Switzerland), lane 2: purified EPO and lane 3: protein ladder (Cat no: 161-0374, Bio-Rad, Hercules, CA). 
(B) 2µg of Purified EPO was separated by SDS-PAGE (12%), then protein was transferred onto 
nitrocellulose membrane and was detected with anti-EPO antibody, lane 1: EPO standard and lane 2: 
purified EPO. (C) Typical profile of a two dimensional gel separation of EPO isoforms. 4µg of both 
purified and commercial EPO standard was analyzed by 2-D electrophoresis, separated by pI 
(ampholytes pH 3-10) in the first dimension followed by SDS-PAGE in the second dimension and 
detected by a western blot.   
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EPO purification from culture supernatant 
 
Selection of elution buffer for affinity 
chromatography: The criterion for the most 
suitable elution buffer is one that dissociates 
EPO from the column but which minimize 
impurities and protein loss. Serum-free CHO 
cell culture supernatant (1L from wave 
bioreactor) was filtered through 0.45µm 
membrane filter and then directly loaded 
onto Blue sepharose column (50ml). To 
eliminate non-specific adsorption caused by 
weak interactions, the column was washed 
properly with 1X PBS. Different elution 
conditions were subsequently tested i.e., step 
elutions with 1, 1.5 and 2 M NaCl in 1X PBS. 
EPO eluted with 1.5 M NaCl was recognized 
as a main band corresponding to EPO 
molecular weight on SDS-PAGE (Fig: 5). 
However, some contaminant protein bands 
with high and low molecular weights were 
present. Faint EPO band was obtained at 1 M 
NaCl and no EPO band was seen at 2 M 
NaCl, however impurities were observed in 
both elutions.  
 
As shown in table 2, higher final EPO 
recovery was obtained with 1.5 M NaCl as 
compared with other concentrations of NaCl, 
60% of EPO was eluted with 1.5 M NaCl, 
whereas only 10% was eluted by 1 M NaCl 
and no EPO was recovered at highest 
concentration of salt in elution buffer. Hence, 
1.5 M NaCl was selected for the elution of 
EPO from the blue sepharose column. 
Approximately 20% of EPO did not bind to 
the column and remained in the supernatant. 
The EPO binding capacity was not increased 
by repeated loading to the column. It is 
possible that the remaining EPO has lower 
carbohydrate content, which could not bind 
properly to blue sepharose. 
 
Table 2. EPO recovery from affinity & ion-exchange chromatography 
Samples           Total EPO (mg)           Percentage of EPO (mg/l) 
Blue sepharose chromatography 
Before loading (culture supernatant)      58.00    100.00 
After loading (flow through)      11.80      20.30 
1 M NaCl eluate       5.95      10.20 
1.5 M NaCl eluate     34.80      60.00 
2 M NaCl eluate                     --                                 -- 
Q-sepharose chromatography 
Before loading (blue sepharose eluate)    33.60    100.00 
After loading (flow through)      2.10         6.25 
140 mM NaCl eluate     23.00      68.40 
250 mM NaCl eluate       6.10      18.15 
500 mM & 1.4 M NaCl eluate              --                     -- 
EPO concentrations in all fractions were determined by ELISA 
 
Selection of elution buffer for Ion-exchange 
chromatography: Desalted blue sepharose 
eluate was applied on to a Q-sepharose 
column (65ml). Various elution conditions 
were tested for high purity and recovery, i.e., 
step elutions with 140, 250, 500 mM and 1.4 
M NaCl in 20 mM Tris (pH-8.0). EPO eluted 
with 140 mM NaCl was recognized as a main 
8
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band corresponding to EPO molecular weight 
on SDS-PAGE (Fig: 5). Other contaminants 
were not observed in this eluate, whereas, 
faint EPO band was seen with 250 mM NaCl 
eluate along with some other contaminant 
protein bands. EPO band was not observed in 
500 mM and 1.4 M elutes, however impurities 
were observed in both elutions. 
 
As shown in table 2, higher final EPO 
recovery was obtained with 140 mM NaCl as 
compared with other concentrations of NaCl, 
68% of EPO was eluted with 140 mM NaCl, 
whereas only 18% was eluted by 250 mM 
NaCl and no EPO were recovered by higher 
concentration of elution buffer. 180 mM & 220 
mM NaCl elutions were also performed but 
very similar results to 250 mM NaCl elution 
was obtained (data not shown). Hence, 140 
mM NaCl was selected for the elution of EPO 
from the Q-sepharose column. 
Approximately 8% of EPO not recovered in 
any fractions, this loss was could be due to 
the desalting.  
 
Table 3. Purification of EPO from 2 liters of cell culture supernatant 
Samples    Total EPO (mg)        Percentage of EPO (mg/l) 
Culture supernatant       116.0   100.00 
Ultra filtration        106.0     91.30 
Blue sepharose         75.6       65.10 
Desalting          70.0     60.30 
Q-sepharose          49.0                                      42.20 
EPO concentrations in all fractions were determined by ELISA 
 
Overall purification process: The final 
scheme of the EPO purification process has 
described here, includes two UF/DF steps 
and two chromatography steps. To optimize 
the purification process for EPO, 2 liters of 
conditioned medium was clarified and 
concentrated to about 2 fold volume 
reductions, concentrated supernatant was 
loaded on to blue sepharose and blue 
sepharose eluate was desalted, and then 
applied on to Q-sepharose column (overall 
process explained as purification in materials 
& methods). The EPO fractions from the Q-
sepharose were buffer exchanged with 
protein storage buffer (Sodium phosphate 
buffer-10 mM, Tris-20 mM and 0.1% of 
Tween 20) and filtered using 0.2µm syringe 
filter and the final solution was stored at 2-
8°C. SDS-PAGE of elutes from each 
chromatography column showed increasing 
purity of the rHuEPO and a single protein 
zone with an apparent molecular mass of 32-
38 kDa. Densitometric scanning of the SDS-
PAGE gels demonstrated that the purity of 
final rHuEPO was >99%. The overall 
recovery of rHuEPO was 42% (Table: 3).  
 
Protein characterization 
Purified EPO was characterized by SDS-
PAGE for the purity and molecular weight 
determination, western blot analysis was 
performed for the specific determination of 
EPO by anti-EPO antibody. 
Isoelectrofocusing was performed for the 
determination of isoforms. The SDS-PAGE 
analysis has shown [Fig: 6(A)] a good level of 
purity, a single protein zone with an apparent 
molecular mass of 34-38 kDa. EPO migrates 
with an apparent size of 34-38 kDa on SDS-
PAGE gels (Jelkmann, 2004). Densitometric 
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scanning of the silver stained gel 
demonstrated that the purity level of final 
purified EPO was >99%. Western-blot 
analysis showed that purified rHuEPO has 
native immunogenicity [Fig: 6(B)]. IEF 
analysis [Fig: 6(C)] showed identical profiles 
for both commercial EPO and purified EPO, 
most glycoforms are found in the 3.5-5.6 pI 
range.  
 
The degree and type of glycosylation of EPO 
is the key factor for in-vivo biological activity 
(Takeuchi et al., 1989). If rHuEPO partially 
deglycosylated during separation, the half-
life of EPO in the blood circulation is very 
much shortened, which includes a significant 
or complete decrease in in-vivo bioactivity 
(Tsuda et al., 1990). Recombinant EPO 
expressed by CHO cells, displays 
physicochemical properties very similar to 
those of native EPO (Davis et al., 1987). Blue 
sepharose affinity chromatography was 
successfully used for the purification of EPO 
by Diana et al. (1995) and Mellado et al. (2007). 
Less expensive (Mellado et al., 2007), higher 
binding efficiency and higher recovery of 
EPO (Diana et al., 1995) facilitates the more 
specific use of blue sepharose rather than 
other affinity ligands for the purification of 
EPO. 
 
In order to develop a simple, inexpensive, 
high-yield method suitable for both small and 
large scale purification of EPO from culture 
supernatant, blue sepharose as pseudo 
affinity chromatography followed by Q-
sepharose ion exchange chromatography was 
used. Various step elution conditions were 
tested for the recovery of EPO by blue 
sepharose column, major band of the EPO 
was observed with the 1.5 M NaCl along with 
some other impurities. More than 50% of 
purity and 70% of recovery was achieved by 
this chromatography, whereas only partial 
purification of EPO was achieved in the 
previous studies (Diana et al., 1995). 
 
EPO eluted with 140 mM NaCl was 
recognized as a main band in Q-sepharose 
column, other contaminant proteins were not 
seen in this elution condition, further increase 
in salt concentration could not elute EPO and 
most of the impurities were eluted. 
Eventhough, the significant EPO band was 
observed at 250 mM NaCl concentration, 140 
mM NaCl was selected for the higher 
recovery and purity of EPO. An acid wash 
(containing 6 M urea, pH-4.7) was performed 
before eluting the EPO from Q-sepharose for 
the removal of unwanted isoforms (lower 
sialylation) and unrelated impurities.  
 
Due to extensive glycosylation, EPO is a 
highly heterogeneous protein, i.e., a complex 
mixture of different, closely related 
glycoforms (Rush et al., 1995). Such 
heterogeneity explains the multiple bands 
observed when purified EPO is analyzed by 
IEF (Gokana et al., 1997). IEF analysis of 
purified EPO showed identical profiles for 
both commercial EPO and purified EPO, 
most glycoforms are found in the 3.5-5.6 pI 
range. Six distinct bands were obtained in the 
purified EPO, whereas seven bands were 
seen in commercial EPO sample. As expected 
most glycoforms are found in the 3.0-5.5 pI 
range. This corresponds to a highly 
glycosylated and sialylated protein with a 
profile showing at least six to seven distinct 
isoforms (Restelli et al., 2006). In the previous 
reports, the recovery and purity of EPO from 
the CHO cell supernatant was 30% & 97% 
(Zanette et al., 2003) and 38% & 99% (Hu et al., 
2004) respectively. Moreover, they used three 
chromatographic steps to achieve the final 
recovery and purity. In present study, more 
than 42% of recovery and >99% of final purity 
was achieved by the simple two step 
purification process.  
 
 
Rambabu Surabattula et al. / Research in Biotechnology, 2(3): 58-74, 2011 
70 
 
 
 
Conclusions 
The selection procedure based on gradual 
increase in MTX concentration rather than 
direct increase in MTX is favored for 
establishment of high producing rCHO cells, 
although it is more time consuming and labor 
intensive. Gradual selection process with 500 
nM MTX was achieved with the stable and 
high expression of recombinant proteins in 
CHO cells. Amplified genes in the CHO cell 
lines are not stable in the absence of MTX. 
Hence, it is essential to add MTX during the 
entire cultivation to maintain the stable and 
constant protein expression. A repeated batch 
process using the novel wave bioreactor 
including perfusion filter was successfully 
developed for high efficient production of 
EPO by CHO cells. First the wave bioreactor 
is successfully applied in repeated batch 
culture of CHO cells. This offers an 
alternative approach for producing gram 
quantities of protein from the industrial cell 
lines.  
 
All these optimized conditions facilitate the 
higher recovery and yields of EPO from the 
cell culture supernatant. Characterization of 
purified EPO showed a very similar identical 
profile compared with commercial EPO 
standard. Hence, it could be used for 
therapeutic and commercial purpose. It is 
believed that besides efficient and reliable 
EPO purification, the process described here 
might have an even more general interest, as 
Blue sepharose based strategies might yield 
interesting results in large scale purification 
of other commercially important 
glycoproteins. This work may be useful for 
further study on a large scale process for 
highly efficient production of proteins toward 
industrial applications. The information 
obtained in this work can be applied to other 
cell cultures, which have wide utilization and 
application. 
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